GLP-1 weight-loss drug in the news as rivals clash over data and rollout; scarce supply and UK debut spark consumer interest.
A wave of recent studies finds GLP-1 weight-loss drugs have variable social and employment impacts beyond health. Observational data hint at temporary gains in dating and job prospects for some women, while other analyses show no long-term causal effects. Experts call for individualized treatment and longer follow-up.
Investors have seen a surge in underwriting and investment banking fees for major banks as AI-driven activity fuels dealmaking. While equity trading benefits from volatility, concerns over chip costs and AI capex weigh on memory and hardware stocks. The Mag Seven faces rotation as growth clusters outperform the top movers.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
[Synopsis here]
Whey protein prices have surged to record levels as demand from GLP-1 weight‑loss drug users and the food industry outpaces supply. Prices for concentrate and 80% whey protein are at records, pushing costs for small brands higher while producers explore blends to ease shortages.
A set of studies and reports show weight-loss drugs can reduce fat while preserving muscle when paired with targeted therapies. Experts emphasize the importance of protein intake and strength training, while researchers investigate how these medications might help combat age-related muscle loss.
A new weight‑loss pill version of semaglutide has launched in the UK for private prescriptions, offering an alternative to injections. The tablet requires strict dosing and a fasting routine and is not yet NHS‑funded. Several outlets warn about counterfeit pills as access broadens.
The wedding dress market is shifting as GLP-1 weight loss drugs become common among engaged couples. Designers report earlier fittings, changed guarantees, and rising alterations costs. Brides worry about weight loss before weddings, while sales staff push early purchases and flexible guarantees.
Novo Nordisk has filed a U.S. lawsuit accusing Eli Lilly of false advertising in campaigns for Zepbound and Mounjaro, alleging the ads compare against older, lower‑dose Wegovy and Ozempic and omit newer high‑dose data. Lilly defends the ads, saying they rely on SURMOUNT‑5 results and will be vigorously defended. The case highlights a battle for GLP‑1 market dominance.